Boston Trust Walden Corp Grows Stock Position in The Cooper Companies, Inc. $COO

Boston Trust Walden Corp grew its position in The Cooper Companies, Inc. (NASDAQ:COO) by 1.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,465,621 shares of the medical device company’s stock after buying an additional 27,644 shares during the quarter. Boston Trust Walden Corp’s holdings in Cooper Companies were worth $104,294,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. TD Asset Management Inc lifted its position in shares of Cooper Companies by 17.3% in the second quarter. TD Asset Management Inc now owns 804,609 shares of the medical device company’s stock valued at $57,256,000 after acquiring an additional 118,411 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Cooper Companies by 81.3% in the second quarter. Sequoia Financial Advisors LLC now owns 6,915 shares of the medical device company’s stock valued at $492,000 after acquiring an additional 3,101 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of Cooper Companies by 19.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 22,890 shares of the medical device company’s stock valued at $1,629,000 after acquiring an additional 3,751 shares in the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of Cooper Companies in the second quarter valued at approximately $2,135,000. Finally, Apollon Wealth Management LLC lifted its position in shares of Cooper Companies by 41.6% in the second quarter. Apollon Wealth Management LLC now owns 4,215 shares of the medical device company’s stock valued at $300,000 after acquiring an additional 1,238 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Insider Activity at Cooper Companies

In other Cooper Companies news, CEO Albert G. White III purchased 10,000 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was bought at an average cost of $68.39 per share, with a total value of $683,900.00. Following the acquisition, the chief executive officer directly owned 226,151 shares of the company’s stock, valued at approximately $15,466,466.89. This represents a 4.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Gerard H. Warner III purchased 1,450 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were acquired at an average cost of $69.23 per share, with a total value of $100,383.50. Following the completion of the acquisition, the chief operating officer directly owned 18,319 shares in the company, valued at $1,268,224.37. The trade was a 8.60% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 17,975 shares of company stock worth $1,216,346 over the last three months. Company insiders own 1.98% of the company’s stock.

Cooper Companies Price Performance

COO stock opened at $69.30 on Tuesday. The business has a fifty day moving average of $69.39 and a two-hundred day moving average of $73.48. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29. The stock has a market cap of $13.78 billion, a price-to-earnings ratio of 34.14, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $109.37.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the firm earned $0.96 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies announced that its board has authorized a stock buyback plan on Wednesday, September 17th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

COO has been the topic of a number of analyst reports. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Tuesday, July 22nd. Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the stock an “equal weight” rating in a research report on Thursday, August 28th. JPMorgan Chase & Co. reduced their price objective on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, August 28th. Needham & Company LLC reiterated a “buy” rating and set a $94.00 price objective on shares of Cooper Companies in a research report on Thursday, August 28th. Finally, Piper Sandler reduced their price objective on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating on the stock in a research report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $84.77.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.